Tenaya Therapeutics Announces RIDGE-1 Clinical Data Presentation at ASGCT 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy TNYA?
Source: Newsfilter
- RIDGE-1 Clinical Trial Data: Tenaya Therapeutics will present new data from the RIDGE-1 trial of TN-401 at the ASGCT 2026 Annual Meeting, featuring safety and efficacy results from both 3E13 vg/kg and 6E13 vg/kg dose cohorts, which is expected to enhance interest in cardiac gene therapy.
- Gene Therapy Innovation: TN-401 aims to deliver a functional PKP2 gene to heart muscle cells using an AAV9 vector to address heart disease caused by PKP2 mutations, potentially offering treatment options for over 70,000 patients in the U.S.
- Multiple Poster Presentations: Tenaya will also showcase a survey on parental perceptions of gene therapy for children with cardiomyopathies and research on TN-501 gene editing therapy at ASGCT, further promoting public awareness and scientific dialogue around gene therapy.
- Webcast Conference Call: Tenaya plans to host a webcast conference call to discuss the clinical data for TN-401 presented at ASGCT, aiming to attract attention from investors and the medical community, thereby enhancing the company's influence in the gene therapy sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNYA
Wall Street analysts forecast TNYA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.848
Low
2.00
Averages
9.14
High
40.00
Current: 0.848
Low
2.00
Averages
9.14
High
40.00
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenaya Therapeutics Announces RIDGE-1 Clinical Data Presentation at ASGCT 2026
- RIDGE-1 Clinical Trial Data: Tenaya Therapeutics will present new data from the RIDGE-1 trial of TN-401 at the ASGCT 2026 Annual Meeting, featuring safety and efficacy results from both 3E13 vg/kg and 6E13 vg/kg dose cohorts, which is expected to enhance interest in cardiac gene therapy.
- Gene Therapy Innovation: TN-401 aims to deliver a functional PKP2 gene to heart muscle cells using an AAV9 vector to address heart disease caused by PKP2 mutations, potentially offering treatment options for over 70,000 patients in the U.S.
- Multiple Poster Presentations: Tenaya will also showcase a survey on parental perceptions of gene therapy for children with cardiomyopathies and research on TN-501 gene editing therapy at ASGCT, further promoting public awareness and scientific dialogue around gene therapy.
- Webcast Conference Call: Tenaya plans to host a webcast conference call to discuss the clinical data for TN-401 presented at ASGCT, aiming to attract attention from investors and the medical community, thereby enhancing the company's influence in the gene therapy sector.
See More
Tenaya Therapeutics Reports Q4 Results and Financing Update
- Earnings Report: Tenaya Therapeutics reported a Q4 GAAP EPS of -$0.12, aligning with market expectations, indicating financial stability amid ongoing operations.
- Cash Reserves Growth: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $100.5 million, a significant increase from $61.4 million in 2024, enhancing financial flexibility for future initiatives.
- Financing Update: The public offering in December 2025 raised net proceeds of $55.8 million after underwriting discounts and expenses, expected to sufficiently fund operations into the second half of 2027, supporting strategic growth plans.
- Collaboration Prospects: Tenaya anticipates an upfront payment from its collaboration with Alnylam, which will further bolster its financial position and support ongoing research and operational activities.
See More
Tenaya's TN-301 Outperforms Givinostat in DMD Cardiomyopathy
- Promising Preclinical Data: At the 2026 Muscular Dystrophy Association conference, Tenaya presented preclinical data showing that TN-301 significantly outperformed the approved pan-HDAC inhibitor Givinostat in improving muscle function and addressing DMD cardiomyopathy, highlighting its potential in treating cardiac, metabolic, and muscular diseases.
- Multi-Modal Mechanism: TN-301 operates through multiple mechanisms, including reducing inflammation and improving mitochondrial function, effectively correcting DMD-associated cardiomyocyte defects, and restoring muscle strength to wild-type levels in mouse models at a low dose of 3 mg/kg, showcasing its superior therapeutic effects.
- Good Safety Profile: In a Phase 1 clinical trial involving healthy adults, TN-301 demonstrated good tolerability across a wide dose range without serious adverse events or dose-limiting toxicities, indicating its safety and efficacy for clinical applications.
- Future Development Plans: Tenaya plans to advance TN-301 into Phase 2 clinical development targeting heart failure and DMD, aiming to address significant unmet needs in current treatments and drive the company's strategic growth in the biopharmaceutical sector.
See More
Tenaya Partners with Alnylam for Heart Drug Development
- Collaboration Details: Tenaya Therapeutics has entered into a partnership with Alnylam Pharmaceuticals to validate up to 15 gene targets, potentially earning up to $1.13 billion in development and commercial milestone payments, highlighting the significant potential in heart disease drug development.
- Upfront Payment Structure: Under the agreement, Tenaya will receive up to $10 million as an upfront payment, which not only provides funding for its research but also lays the groundwork for subsequent drug development efforts.
- Market Reaction Analysis: Following the announcement, Tenaya's stock surged 41% during regular trading but pulled back 5% in after-hours trading, reflecting a blend of initial market optimism and subsequent caution regarding the collaboration.
- Investor Sentiment Shift: On the Stocktwits platform, retail sentiment around TNYA stock shifted from 'bearish' to 'bullish' over the past 24 hours, indicating investor optimism about Tenaya's future gene therapy TN401, especially in the absence of curative competition.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Tenaya Therapeutics Partners with Alnylam for Genetic Research
- Collaboration Agreement: Tenaya Therapeutics has entered into a research collaboration with Alnylam Pharmaceuticals focused on identifying genetic targets for cardiovascular diseases, with Tenaya set to validate up to 15 gene targets and potentially receive $10 million upfront and up to $1.13 billion in milestone payments, significantly enhancing its research capabilities.
- Technical Advantages: Tenaya employs human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for high-throughput genetic target identification, alongside engineered heart tissue and preclinical in vivo models for validation, having generated over 150 genetic targets that contribute to the development of clinical-stage candidates.
- Clinical Trial Progress: In December 2025, Tenaya shared interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for rare inherited heart disease, reporting safety, biopsy, and arrhythmia results from three patients, indicating the therapy's potential in treating such conditions.
- Market Performance Analysis: Despite a 31.20% increase to 76 cents, Tenaya's stock remains 29.1% and 23.6% below its 100-day and 200-day simple moving averages, indicating a bearish trend in the medium to long term, with analysts generally rating it as a
See More
Tenaya Therapeutics Announces RIDGE-1 Clinical Data Presentation at ASGCT 2026
- RIDGE-1 Clinical Trial Data: Tenaya Therapeutics will present new data from the RIDGE-1 trial of TN-401 at the ASGCT 2026 Annual Meeting, featuring safety and efficacy results from both 3E13 vg/kg and 6E13 vg/kg dose cohorts, which is expected to enhance interest in cardiac gene therapy.
- Gene Therapy Innovation: TN-401 aims to deliver a functional PKP2 gene to heart muscle cells using an AAV9 vector to address heart disease caused by PKP2 mutations, potentially offering treatment options for over 70,000 patients in the U.S.
- Multiple Poster Presentations: Tenaya will also showcase a survey on parental perceptions of gene therapy for children with cardiomyopathies and research on TN-501 gene editing therapy at ASGCT, further promoting public awareness and scientific dialogue around gene therapy.
- Webcast Conference Call: Tenaya plans to host a webcast conference call to discuss the clinical data for TN-401 presented at ASGCT, aiming to attract attention from investors and the medical community, thereby enhancing the company's influence in the gene therapy sector.
See More
Tenaya Therapeutics Reports Q4 Results and Financing Update
- Earnings Report: Tenaya Therapeutics reported a Q4 GAAP EPS of -$0.12, aligning with market expectations, indicating financial stability amid ongoing operations.
- Cash Reserves Growth: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $100.5 million, a significant increase from $61.4 million in 2024, enhancing financial flexibility for future initiatives.
- Financing Update: The public offering in December 2025 raised net proceeds of $55.8 million after underwriting discounts and expenses, expected to sufficiently fund operations into the second half of 2027, supporting strategic growth plans.
- Collaboration Prospects: Tenaya anticipates an upfront payment from its collaboration with Alnylam, which will further bolster its financial position and support ongoing research and operational activities.
See More
Tenaya's TN-301 Outperforms Givinostat in DMD Cardiomyopathy
- Promising Preclinical Data: At the 2026 Muscular Dystrophy Association conference, Tenaya presented preclinical data showing that TN-301 significantly outperformed the approved pan-HDAC inhibitor Givinostat in improving muscle function and addressing DMD cardiomyopathy, highlighting its potential in treating cardiac, metabolic, and muscular diseases.
- Multi-Modal Mechanism: TN-301 operates through multiple mechanisms, including reducing inflammation and improving mitochondrial function, effectively correcting DMD-associated cardiomyocyte defects, and restoring muscle strength to wild-type levels in mouse models at a low dose of 3 mg/kg, showcasing its superior therapeutic effects.
- Good Safety Profile: In a Phase 1 clinical trial involving healthy adults, TN-301 demonstrated good tolerability across a wide dose range without serious adverse events or dose-limiting toxicities, indicating its safety and efficacy for clinical applications.
- Future Development Plans: Tenaya plans to advance TN-301 into Phase 2 clinical development targeting heart failure and DMD, aiming to address significant unmet needs in current treatments and drive the company's strategic growth in the biopharmaceutical sector.
See More
Tenaya Partners with Alnylam for Heart Drug Development
- Collaboration Details: Tenaya Therapeutics has entered into a partnership with Alnylam Pharmaceuticals to validate up to 15 gene targets, potentially earning up to $1.13 billion in development and commercial milestone payments, highlighting the significant potential in heart disease drug development.
- Upfront Payment Structure: Under the agreement, Tenaya will receive up to $10 million as an upfront payment, which not only provides funding for its research but also lays the groundwork for subsequent drug development efforts.
- Market Reaction Analysis: Following the announcement, Tenaya's stock surged 41% during regular trading but pulled back 5% in after-hours trading, reflecting a blend of initial market optimism and subsequent caution regarding the collaboration.
- Investor Sentiment Shift: On the Stocktwits platform, retail sentiment around TNYA stock shifted from 'bearish' to 'bullish' over the past 24 hours, indicating investor optimism about Tenaya's future gene therapy TN401, especially in the absence of curative competition.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Tenaya Therapeutics Partners with Alnylam for Genetic Research
- Collaboration Agreement: Tenaya Therapeutics has entered into a research collaboration with Alnylam Pharmaceuticals focused on identifying genetic targets for cardiovascular diseases, with Tenaya set to validate up to 15 gene targets and potentially receive $10 million upfront and up to $1.13 billion in milestone payments, significantly enhancing its research capabilities.
- Technical Advantages: Tenaya employs human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for high-throughput genetic target identification, alongside engineered heart tissue and preclinical in vivo models for validation, having generated over 150 genetic targets that contribute to the development of clinical-stage candidates.
- Clinical Trial Progress: In December 2025, Tenaya shared interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for rare inherited heart disease, reporting safety, biopsy, and arrhythmia results from three patients, indicating the therapy's potential in treating such conditions.
- Market Performance Analysis: Despite a 31.20% increase to 76 cents, Tenaya's stock remains 29.1% and 23.6% below its 100-day and 200-day simple moving averages, indicating a bearish trend in the medium to long term, with analysts generally rating it as a
See More
